TG THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.48 USD | -5.40% |
|
-0.84% | -3.51% |
| May. 01 | Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts | MT |
| May. 01 | Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 309M | Sales 2025 * | 472M | Capitalization | 2.36B |
|---|---|---|---|---|---|
| Net income 2024 * | -3M | Net income 2025 * | 101M | EV / Sales 2024 * | 7.57 x |
| Net cash position 2024 * | 20.93M | Net cash position 2025 * | 113M | EV / Sales 2025 * | 4.76 x |
| P/E ratio 2024 * |
-749
x | P/E ratio 2025 * |
25.5
x | Employees | 284 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on TG Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -5.40% | ||
| 1 week | -0.84% | ||
| Current month | +20.64% | ||
| 1 month | +19.25% | ||
| 3 months | +19.16% | ||
| 6 months | +36.54% | ||
| Current year | -3.51% |
1 week
16.34
18.41
1 month
12.9318.41
Current year
12.8422.67
1 year
6.4630.84
3 years
3.4841.00
5 years
3.4856.74
10 years
3.3256.74
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Sean Power
DFI | Director of Finance/CFO | 42 | 11-12-28 |
Jenna A. Bosco
IRC | Investor Relations Contact | - | 11-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Laurence Charney
BRD | Director/Board Member | 76 | 12-02-29 |
Kenneth Hoberman
BRD | Director/Board Member | 59 | 14-12-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 16.48 | -5.40% | 3,268,639 |
| 24-05-16 | 17.42 | -1.69% | 2,024,771 |
| 24-05-15 | 17.72 | -1.34% | 3,437,460 |
| 24-05-14 | 17.96 | +3.70% | 3,738,812 |
| 24-05-13 | 17.32 | +4.21% | 4,316,617 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Calendar
2024-06-14
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
16.48
USD
Average target price
31.5
USD
Spread / Average Target
+91.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.51% | 2.36B | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +28.31% | 12.16B | |
| +24.73% | 12.17B |
- Stock Market
- Equities
- TGTX Stock
